StockNews.com started coverage on shares of Veradigm (NASDAQ:MDRX – Free Report) in a research report sent to investors on Wednesday morning. The firm issued a hold rating on the software maker’s stock.
Separately, Stephens lifted their target price on shares of Veradigm from $7.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, January 31st.
View Our Latest Research Report on MDRX
Veradigm Price Performance
About Veradigm
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Read More
- Five stocks we like better than Veradigm
- Retail Stocks Investing, Explained
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What Are Dividend Champions? How to Invest in the Champions
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.
